Suxia Luo

498 total citations
17 papers, 73 citations indexed

About

Suxia Luo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Suxia Luo has authored 17 papers receiving a total of 73 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 5 papers in Surgery. Recurrent topics in Suxia Luo's work include Gastric Cancer Management and Outcomes (8 papers), Cancer Research and Treatments (4 papers) and Pancreatic and Hepatic Oncology Research (3 papers). Suxia Luo is often cited by papers focused on Gastric Cancer Management and Outcomes (8 papers), Cancer Research and Treatments (4 papers) and Pancreatic and Hepatic Oncology Research (3 papers). Suxia Luo collaborates with scholars based in China, United Kingdom and Australia. Suxia Luo's co-authors include Zhixiang Zhuang, Dan‐Yun Ruan, Liangyu Bie, Yingmei Guo, Jing Li, Yuxian Bai, Yanqiao Zhang, Junye Wang, Xiaohua Liang and Funan Liu and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Surgical Oncology.

In The Last Decade

Suxia Luo

15 papers receiving 71 citations

Peers

Suxia Luo

ONCOL

PRM

SURGE

GASTR

IMMUN

Natalia Fadeeva Russia

Hwoei Fen Soo Hoo Malaysia

Sang-Young Roh South Korea

Sergey Lazarev Russia

M. Díez García Spain

Carlos Adame United States

Theresa Baumeister Germany

Yaelle Tuvy United States

Eric Lander United States

Natalia Fadeeva Russia

Suxia Luo

46 ×1.0

ONCOL

53 ×1.4

PRM

23 ×1.2

SURGE

15 ×0.9

GASTR

8 ×0.6

IMMUN

Citations per year, relative to Suxia Luo Suxia Luo (= 1×) peers Natalia Fadeeva

Countries citing papers authored by Suxia Luo

Since Specialization

Citations

This map shows the geographic impact of Suxia Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suxia Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suxia Luo more than expected).

Fields of papers citing papers by Suxia Luo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suxia Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suxia Luo. The network helps show where Suxia Luo may publish in the future.

Co-authorship network of co-authors of Suxia Luo

This figure shows the co-authorship network connecting the top 25 collaborators of Suxia Luo. A scholar is included among the top collaborators of Suxia Luo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suxia Luo. Suxia Luo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Wang, Yusheng, Wenhui Yang, Yunfeng Li, et al.. (2025). QL1203 vs placebo plus mFOLFOX6 as first-line therapy in RAS wild-type, metastatic colorectal cancer (mCRC): Interim analysis (IA) of a multicenter, randomized, double-blinded, parallel, phase 3 trial.. Journal of Clinical Oncology. 43(4_suppl). 190–190.

Ma, Fei, Suxia Luo, Bin Zhang, et al.. (2025). PD-1 inhibitor (sintilimab) and fruquintinib plus SOX as conversion therapy for initially unresectable gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from a single-arm, phase 2 clinical trial.. Journal of Clinical Oncology. 43(4_suppl). 406–406. 1 indexed citations

Bie, Liangyu, Wei Chen, Suxia Luo, et al.. (2025). Benmelstobart plus anlotinib and chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: A phase 2 study. Cell Reports Medicine. 6(6). 102145–102145.

Li, Zhi, Wei Chen, Jian Zhang, et al.. (2025). Neoadjuvant camrelizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma: a single-arm, phase 2 trial. Gastric Cancer. 28(4). 652–661. 1 indexed citations

Ma, Fei, Suxia Luo, Bin Zhang, et al.. (2024). Fruquintinib combined with sintilimab and SOX as conversion therapy for unresectable locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): A single-arm, open-label, phase 2 clinical trial.. Journal of Clinical Oncology. 42(16_suppl). e16021–e16021. 1 indexed citations

Li, Zhi, Qiang Fu, Bin Zhang, et al.. (2024). Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study. International Journal of Surgery. 110(4). 2071–2084. 13 indexed citations

Pan, Hongming, Tianshu Liu, Nong Xu, et al.. (2023). A multicenter, phase 1 study of AB011, a recombinant humanized anti-CLDN18.2 monoclonal antibody, as monotherapy and combined with capecitabine and oxaliplatin (CAPOX) in patients with advanced solid tumors.. Journal of Clinical Oncology. 41(4_suppl). 391–391. 8 indexed citations

Xu, Jianming, Haiping Jiang, Kangsheng Gu, et al.. (2023). Abstract CT078: First-line treatment with sintilimab (sin) vs placebo in combination with chemotherapy (chemo) in patients (pts) with unresectable gastric or gastroesophageal junction (G/GEJ) cancer: Final overall survival (OS) results from the randomized, phase III ORIENT-16 trial. Cancer Research. 83(8_Supplement). CT078–CT078. 11 indexed citations

Xu, Rui‐Hua, Dan‐Yun Ruan, Furong Liu, et al.. (2023). A phase 1 trial of claudin 18.2-specific antibody-drug conjugate CMG901 in patients with advanced gastric/gastroesophageal junction cancer.. Journal of Clinical Oncology. 41(36_suppl). 434420–434420. 13 indexed citations

10.

Cui, Jiuwei, Naifei Chen, Chengfei Pu, et al.. (2022). A phase 1 dose-escalation study of GCC19 CART a novel coupled CAR therapy for subjects with metastatic colorectal cancer.. Journal of Clinical Oncology. 40(16_suppl). 3582–3582. 5 indexed citations

11.

Shen, Lin, Xichun Hu, Ning Li, et al.. (2022). A phase Ia/Ib study of CBP-1008, a bispecific ligand drug conjugate, in patients with advanced solid tumors.. Journal of Clinical Oncology. 40(16_suppl). 3000–3000. 5 indexed citations

12.

Liu, Dan, Jifang Gong, Xiaotian Zhang, et al.. (2022). A Phase Ib Study of KN026, a Bispecific Anti-HER2 Antibody, Combined with KN046, an Anti-CTLA-4/PD-L1 Antibody, in Patients with HER2-Positive Advanced Gastrointestinal Cancer. SSRN Electronic Journal. 1 indexed citations

13.

Liu, Baogang, Dongqing Lv, Ying Cheng, et al.. (2022). Phase I/IIa study of PM8001, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with advanced tumors.. Journal of Clinical Oncology. 40(16_suppl). 2512–2512. 7 indexed citations

14.

Xu, Jianming, Rongrui Liu, Jieer Ying, et al.. (2022). A phase II study evaluating KN026 monotherapy in patients (pts) with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancers (GC/GEJC).. Journal of Clinical Oncology. 40(16_suppl). 4040–4040. 3 indexed citations

15.

Gu, Shanzhi, Paul L. de Souza, Yuankai Shi, et al.. (2022). A phase I dose-escalation and expansion study of HBM4003, an anti-CTLA-4 heavy chain only monoclonal antibody, in patients with advanced solid tumors.. Journal of Clinical Oncology. 40(16_suppl). 2641–2641. 2 indexed citations

16.

Li, Juntao, et al.. (2021). Correction to: Impact of Ipsilateral Supraclavicular Lymph Node Dissection (ISLND) for Breast Cancer Patients and a Nomogram for Predicting Ipsilateral Supraclavicular Pathological Complete Response (ispCR). Annals of Surgical Oncology. 28(S3). 871–871. 1 indexed citations

17.

Chen, Xiaobing, Beibei Chen, Jian Li, et al.. (2013). [Effects of 5-Aza-dC on 5-Fu chemosensitivity by modulating TIP30 gene expression in human colorectal cancer cells].. PubMed. 35(11). 824–7. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact